Devonian Health Group Inc. (Devonian) announced its presence at the upcoming 6th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases (ADDDS) held on November 1-3, 2022, in Boston, MA, USA. During this summit, the Corporation will present ThykamineTM's Phase 2 clinical trial results in Atopic dermatitis and other targeted skin inflammatory therapeutic applications. Details of the Oral presentation are as follows: Title: ThykamineTM A New Botanical Drug: A Serious Candidate for the treatment of Atopic dermatitis & Beyond.

Session: Emerging Clinical Candidates & Therapeutic Options: Date/Time: November 3rd, 2022, 13:40pm-14:10pm (EST).